INTRODUCTION
There are currently no effective pharmacological therapies for primary or recurrent prostate cancer. Androgen-deprivation therapy only provides a temporary inhibition of the cancer growth before the hormone-refractory form of prostate cancer develops. Moreover, no effective pharmacological treatments exist for elimination of residual cancer cells after prostate cancer surgery.
We propose here transcription factor Stat5a/b as a potential therapeutic target for prostate cancer.
Stat5 is one of the seven members of Stat gene family of transcription factors (1) . Two highly homologous isoforms of Stat5, 94-kDa Stat5a and 92-kDa Stat5b, are encoded by separate genes (1).
Stat5a and Stat5b (hereafter referred to as Stat5a/b) are latent cytoplasmic proteins that act as both cytoplasmic signaling proteins and nuclear transcription factors. Phosphorylation of a specific tyrosine residue in the carboxy-terminal domain (1) by a tyrosine kinase, typically of the Jak protein family (2, 3) , activates Stat5a/b. After phosphorylation, Stat5a and Stat5b homo-or hetero-dimerize and translocate to the nucleus where they bind to specific Stat5a/b response elements of target gene promoters (1) .
Stat5 proteins are divided into five structurally and functionally conserved domains. The Nterminal domain is involved in stabilizing interactions between two Stat5 dimers to form tetramers, 4 which are needed for maximal transcriptional activation of weak promoters (4) . Next to the N-terminal domain is the coiled-coil domain which facilitates protein-protein interactions (5, 6) important for transcriptional regulation. The DNA-binding domain mediates direct binding of Stat5a/b to DNA and recognizes members of the GAS family of enhancers (7) . The stability of DNA-binding is modified by the adjacent linker domain. The most highly conserved domain of Stat5a/b proteins is the SH2 domain which mediates both receptor-specific recruitment and STAT dimerization (8) . Specifically, dimerization requires the binding of a phosphorylated tyrosine residue of one Stat5a/b subunit to the SH2 domain of the other subunit (7) . Finally, the carboxy terminus carries a transactivation domain (TAD), which varies considerably in both length and sequence between different Stat family members.
TAD binds critical co-activators and is directly involved in facilitating the initiation of transcription (7, 9) . Stat5a has 20 amino acids that are unique in its C-terminal sequence, while eight amino acids in the C-terminus are specific to Stat5b. Furthermore, Stat5b has a five residue abbreviation of the Stat5a phosphotyrosyl tail segment between the SH2 and TA domains. Stat5a/b is constitutively active in human prostate cancer but not in normal prostate epithelium (10, 11) . Activation of Stat5a/b in primary prostate cancer predicted early prostate cancer recurrence (12) . We have shown in two separate clinical prostate cancer populations that activation of Stat5a/b is associated with high histological grade of prostate cancer (11, 12) . Factors that activate Stat5a/b in prostate cancer include prolactin (Prl), a locally produced mitogen in prostate cancer cells (11, 13, 14) .
Prl expression in prostate cancer, similar to activation of Stat5a/b, is associated with high histological grade of the cancer (11) . Transgenic mice overexpressing Prl develop massive prostate enlargement (15) (16) (17) , and prostates of Prl null mice were smaller than their wild-type counterparts (18) . Correspondingly, the prostate acinar epithelium of Stat5a null mice was defective (19) .
We have previously shown that adenoviral expression of a dominant-negative (DN) mutant of Stat5a, blocking both Stat5a and Stat5b, induced apoptotic death of human prostate cancer cells in culture (10) . This Stat5a mutant lacked the transactivation domain, and thus was able to dimerize and bind to DNA, but was unable to initiate transcription (10) . This finding was later confirmed in TRAMP mouse tumor model using an over-expression model of an analogous truncation mutant of Stat5b that blocked both Stat5a and Stat5b (20 Statistical methods. Tumor growth was modeled using mixed effects linear regression analysis.
Tumor volumes were log-transformed in order to satisfy the assumption of normality. Separate slopes and intercepts were assumed for each group, and a random intercept term was included to account for correlation among repeated measurements from the same mouse. Stat5a/5b inhibited mice were compared with both control groups with respect to the rate of tumor growth (slopes) and model estimated mean tumor volume at 36 days. All analyses were performed using SAS Version 9.1.3 (SAS Institute, Cary, NC). (Fig. 1A) . Infection of CWR22Rv cells with adenovirus expressing beta-Galactosidase (AdLacZ) followed by beta-Galactosidase-staining showed 90-95% transfection efficiency (data not shown). CWR22Rv cells were infected with AdWTStat5b or AdDNStat5a/b, with mock-infected cells as a control, and cells were seeded the next day at different densities for the clonogenic survival assay (Fig. 3A) . After 21 days, surviving clones were counted and photographed (Fig. 3A) . Whole cell lysates of the same samples were immunoblotted for phospho-Stat3, total Stat3 and actin. plaque-forming units per tumor every third day for 9 days (days 11, 14 and 17). Tumor volumes were calculated using the formula (length x width x depth x 0.5236).
RESULTS AND DISCUSSION

